Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Total Liabilities (2023 - 2025)

CG Oncology (CGON) has disclosed Total Liabilities for 3 consecutive years, with $39.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Liabilities rose 82.03% year-over-year to $39.0 million, compared with a TTM value of $39.0 million through Dec 2025, up 82.03%, and an annual FY2025 reading of $39.0 million, up 82.03% over the prior year.
  • Total Liabilities was $39.0 million for Q4 2025 at CG Oncology, down from $42.3 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $107.6 million in Q3 2023 and bottomed at $10.2 million in Q1 2024.
  • Average Total Liabilities over 3 years is $41.7 million, with a median of $27.3 million recorded in 2025.
  • The sharpest move saw Total Liabilities crashed 88.19% in 2024, then surged 169.22% in 2025.
  • Year by year, Total Liabilities stood at $14.5 million in 2023, then skyrocketed by 47.61% to $21.4 million in 2024, then surged by 82.03% to $39.0 million in 2025.
  • Business Quant data shows Total Liabilities for CGON at $39.0 million in Q4 2025, $42.3 million in Q3 2025, and $31.1 million in Q2 2025.